[go: up one dir, main page]

WO2020120965A1 - Cellules modifiées utiles pour une méthode thérapeutique - Google Patents

Cellules modifiées utiles pour une méthode thérapeutique Download PDF

Info

Publication number
WO2020120965A1
WO2020120965A1 PCT/GB2019/053514 GB2019053514W WO2020120965A1 WO 2020120965 A1 WO2020120965 A1 WO 2020120965A1 GB 2019053514 W GB2019053514 W GB 2019053514W WO 2020120965 A1 WO2020120965 A1 WO 2020120965A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
cell
cells
fcrl3
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2019/053514
Other languages
English (en)
Inventor
Julie GLANVILLE
Andrew Mcmichael
Tao Dong
Anne-Marie MOODY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Imperial College of London
Original Assignee
Oxford University Innovation Ltd
Imperial College of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd, Imperial College of London filed Critical Oxford University Innovation Ltd
Publication of WO2020120965A1 publication Critical patent/WO2020120965A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the present invention relates to methods for the treatment of diseases such as cancer or viral infections in which the therapy is mediated by cells, for example T cells, caused to express specific cell surface receptors.
  • Cytotoxic T lymphocytes that encounter antigen proliferate from a single naive T-cell to form a population with diverse effector function and differentiation states, that control and prevent infection and cancer.
  • Antigen-specific CTL are extremely heterogeneous in terms of clonotype, differentiation state and efficacy. Factors that define CTL of superior efficacy are well explored.
  • TCR signal strength is known to modulate the breadth and magnitude of CTL effector functions, and epigenetic marks modulate intrinsic states such as exhaustion that limit activation. It is not clear if or how TCR signal strength modulates contact-dependent killing, and TCR affinity, TCR avidity, or factors downstream of the TCR could all contribute.
  • CD8 + cytotoxic T lymphocytes are serial killers, polarizing the cytoskeleton to form kinapses, from which cortical actin briefly clears to permit cytotoxic granule fusion at the cell membrane (Ritter et al. (2017) Proc Natl Acad Sci U S A 1 14(32) ⁇ 6585-E6594), enabling targeted delivery of lytic molecules (Halle et al (2017) Trends Immunol).
  • Contact-dependent killing and other effector functions are triggered at different signalling thresholds in response to antigen engagement by the T cell receptor (TCR) (Valitutti et al (1996). J Exp Med 183(4): 1917—1921 ) (3).
  • any given CTL is governed by antigen dose and the efficiency of signal transduction, which in turn dictates antigen sensitivity.
  • the protective capabilities of HIV-1 -specific CTLs have been variously attributed to polyfunctionality (Betts et al. (2006) Blood 107(12):4781 - 4789), cytotoxic activity (McMichael & Jones (2010) Science 330(6010):1488-1490), and in vitro suppression of viral replication (Saez-Cirion et al. (2007) Proc Natl Acad Sci U S A 104(16):6776- 6781).
  • TCR-identical CTLs isolated from individual donors can exhibit similar levels of heterogeneity with respect to cytokine production, contact-dependent killing, and suppression of viral replication in vitro.
  • Expression of specific coreceptors on the cell surface of the T cells has been shown in the present invention to trigger contact-dependent killing at lower epitope densities in the more potent CTLs.
  • the coreceptors incorporate tyrosine-based activation or inhibition motifs.
  • the most effective coreceptor has been shown in the present invention to be FCRL3.
  • CD8 + CTLs protect against life-threatening viral infections and cancer. This daunting task is made possible by a process of gene recombination that can generate billions of unique T-cell receptors (TCRs).
  • TCRs T-cell receptors
  • the present invention challenges the concept that the TCR is the major determinant of CTL efficacy.
  • the inventors have observed a striking degree of functional heterogeneity among TCR- identical human CTLs. It has been found that cytolytic activity and antiviral potency are dictated by TCR-mediated signal summation, and further identified co-receptors that modulate the activation threshold in response to antigen-triggered ligation of the TCR.
  • a genetically engineered cell comprising a receptor that comprises an antigen binding domain and a T-cell activating function and at least one co-receptor which modulates the activity of the receptor, wherein the cell overexpresses the coreceptor and in which the co-receptor is selected from the group consisting of Fc-Receptor-Like-3 (FCRL3), Fc-Receptor-Like-6 (FCRL6), and Leucine-Rich-Repeat-Neuronal-3 (LRRN3).
  • FCRL3 Fc-Receptor-Like-3
  • FCRL6 Fc-Receptor-Like-6
  • LRRN3 Leucine-Rich-Repeat-Neuronal-3
  • the co-receptor is overexpressed compared to a control (i.e. an unmodified cell where expression of the co-receptor has not been altered).
  • the cell is therefore a genetically engineered cell which overexpresses the co-receptor.
  • the cell of the invention may possess an improved function or activity such as for example an improved cytotoxic activity (i.e. cell killing activity, for example T cell medicated cell killing). Expression of one of these co-receptors can provide improved activity (i.e. cell killing activity) in transduced or transfected cells compared with control cells not expressing the co-receptor.
  • the co-receptor may therefore be described as being a heterologous co-receptor with respect to the cell in which it is overexpressed.
  • the cell is transfected or transduced by any convenient method of genetic engineering to overexpress the co-receptor.
  • the receptor may be a T cell receptor (TCR) or a chimeric antigen receptor (CAR).
  • TCR T cell receptor
  • CAR chimeric antigen receptor
  • the cell is also genetically engineered to express the CAR.
  • the cell is also genetically engineered to express the modified T cell receptor or heterologous T cell receptor.
  • the T cell receptor may be native to the cell it is expressed in, i.e. an autologous T cell receptor from the same individual the T cell is from.
  • the T cell receptor may also be a heterologous recombinant protein expressed on the surface of the cell which is transduced or transfected with a nucleic acid sequence encoding the TCR.
  • the TCR may therefore be an autologous TCR or a heterologous TCR.
  • the chimeric antigen receptor is a recombinant receptor that comprises an antigen binding domain and a T-cell activating function (so-called first-generation CARs).
  • the CAR may additionally comprise a costimulatory domain of a costimulatory receptor (so-called second- generation CARs), or the CAR may comprise 2 costimulatory domains combined with an activation domain in their cytoplasmic domain (so-called third-generation CARs).
  • a CAR is a heterologous recombinant protein expressed on the surface of a cell which is transduced or transfected with a nucleic acid sequence encoding the CAR.
  • the modulation of the activity of the receptor provided by the co-receptor may be activation (upregulation) or inhibition (downregulation).
  • the activation represents enhancement of the activity of the T cell killing activity of the cell.
  • the inhibition represents repression of the activity of the T cell killing activity of the cell.
  • the co-receptor is a recombinant receptor comprising one or more of FCRL3, FCRL6, LRRN3 which are therefore heterologous to the cell in which the co-receptor is expressed.
  • the co-receptor is expressed on the surface of the cell which is transduced or transfected with a nucleic acid sequence or sequences encoding the co-receptor or co-receptors.
  • the co-receptor may be co-expressed with the CAR.
  • FCRL3 is a glycoprotein and a member of the immunoglobulin receptor superfamily.
  • the protein comprises cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) and immunoreceptor tyrosine-based inhibition motifs (ITIMs).
  • ITAMs cytoplasmic immunoreceptor tyrosine-based activation motifs
  • ITIMs immunoreceptor tyrosine-based inhibition motifs
  • the FCRL3 co-receptor may have the nucleic acid coding sequence or amino acid sequence as shown in Figure 6 or an isoform as shown in Figure 7 or a sequence substantially identical thereto, suitably 75%, 80%, 85%, 90%, 95%, 99% identical thereto.
  • CTL cytotoxic T-lymphocyte
  • FCRL6 is a glycoprotein and a member of the immunoglobulin receptor superfamily.
  • the protein comprises cytoplasmic immunoreceptor tyrosine-based inhibition motifs (ITIMs).
  • the FCRL6 coreceptor may have the nucleic acid coding sequence or amino acid sequence as shown in Figure 1 1 or a sequence substantially identical thereto, suitably 75%, 80%, 85%, 90%, 95%, 99% identical thereto.
  • FCRL6 reduces the CTL cell mediated killing activity of the TCR or CAR.
  • LRRN3 is a transmembrane protein with an immunoglobulin domain and a previously unreported cytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM).
  • the LRRN3 co-receptor may have the nucleic acid coding sequence or amino acid sequence as shown in Figure 10 or a sequence substantially identical thereto, suitably 75%, 80%, 85%, 90%, 95%, 99% identical thereto.
  • LRRN3 reduces the CTL cell mediated killing activity of the TCR or CAR.
  • protein in this text means, in general terms, a plurality of amino acid residues joined together by peptide bonds. It is used interchangeably and means the same as peptide, oligopeptide, oligomer or polypeptide, and includes glycoproteins and derivatives thereof.
  • protein is also intended to include fragments, analogues and derivatives of a protein wherein the fragment, analogue or derivative retains essentially the same biological activity or function as a reference protein.
  • the fragment, analogue or derivative of the protein as defined in this text may be at least 6, preferably 10 or 20, or up to 50 or 100 amino acids long.
  • the fragment, derivative or analogue of the protein may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably, a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence which is employed for purification of the polypeptide.
  • a conserved or non-conserved amino acid residue preferably, a conserved amino acid residue
  • substituted amino acid residue may or may not be one encoded by the genetic code
  • one or more of the amino acid residues includes a substituent group
  • silent substitutions, additions and deletions which do not alter the properties and activities of the protein of the present invention.
  • Conservative substitutions which do not alter the properties and activities of the protein are especially preferred.
  • An example of a variant of the present invention is a fusion protein as defined above, apart from the substitution of one or more amino acids with one or more other amino acids.
  • the skilled person is aware that various amino acids have similar properties.
  • One or more such amino acids of a substance can often be substituted by one or more other such amino acids without eliminating a desired activity of that substance.
  • amino acids glycine, alanine, valine, leucine and isoleucine can often be substituted for one another (amino acids having aliphatic side chains). Of these possible substitutions, it may be preferred that glycine and alanine are used to substitute for one another (since they have relatively short side chains) and that valine, leucine and isoleucine are used to substitute for one another (since they have larger aliphatic side chains which are hydrophobic).
  • amino acids which can often be substituted for one another include: phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains); lysine, arginine and histidine (amino acids having basic side chains); aspartate and glutamate (amino acids having acidic side chains); asparagine and glutamine (amino acids having amide side chains); and cysteine and methionine (amino acids having sulphur containing side chains). Substitutions of this nature are often referred to as“conservative” or“semi- conservative” amino acid substitutions.
  • Amino acid deletions or insertions may also be made relative to the amino acid sequence for the fusion protein referred to above.
  • amino acids which do not have a substantial effect on the activity of the polypeptide, or at least which do not eliminate such activity may be deleted.
  • Such deletions can be advantageous since the overall length and the molecular weight of a polypeptide can be reduced whilst still retaining activity. This can enable the amount of polypeptide required for a particular purpose to be reduced - for example, dosage levels can be reduced.
  • Amino acid insertions relative to the sequence of the fusion protein above can also be made. This may be done to alter the properties of a substance of the present invention (e.g. to assist in identification, purification or expression, as explained above in relation to fusion proteins).
  • Amino acid changes relative to the sequence for the fusion protein of the invention can be made using any suitable technique e.g. by using site-directed mutagenesis. It should be appreciated that amino acid substitutions or insertions within the scope of the present invention can be made using naturally occurring or non-naturally occurring amino acids. Whether or not natural or synthetic amino acids are used, it is preferred that only L- amino acids are present.
  • a protein according to the invention may have additional N-terminal and/or C-terminal amino acid sequences. Such sequences can be provided for various reasons, for example, glycosylation.
  • fusion protein in this text means, in general terms, one or more proteins joined together by chemical means, including hydrogen bonds or salt bridges, or by peptide bonds through protein synthesis or both.
  • Identity as known in the art is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness (homology) between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. While there exist a number of methods to measure identity between two polypeptides or two polynucleotide sequences, methods commonly employed to determine identity are codified in computer programs.
  • Preferred computer programs to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, et al., Nucleic acids Research, 12, 387 (1984), BLASTP, BLASTN, and FASTA (Atschul et al., J. Molec. Biol. 215, 403 (1990).
  • the antigen binding domain of the CAR may recognise an epitope on an antigen presented by a disease-causing agent such as a virus or a cancerous or precancerous cell.
  • the virus may be a retrovirus, for example a human immunodeficiency virus, e.g. HIV-1 , or HIV-2, or human lymphotropic virus (HTLV-1), human immunodeficiency virus 1.
  • a human immunodeficiency virus e.g. HIV-1 , or HIV-2
  • HTLV-1 human lymphotropic virus
  • the antigen may be tumour antigen such as CD52, PD-L1 , CTLA4, CD20, PD-1 receptor, CD19. CD47, PD-1 (or CD279).
  • the T-cell activating function includes effector domains such as O ⁇ 3-z or Fc receptor g (FcR y).
  • the co-stimulatory domain of a costimulatory receptor includes effector domains such as CD28, 4- 1 BB, DAP10, 0X40, or ICOS.
  • the activation domain may be a CD28 domain.
  • First generation CARs include chimeric molecules between O ⁇ 3-z or Fc receptor g and CD8, CD4, CD25, or CD16.
  • Second-generation CARs include receptors encompassing the O ⁇ 3-z chain, and the cytoplasmic domain of a costimulatory receptor such as CD28, 4-1 BB, DAP10, 0X40, or ICOS.
  • a costimulatory receptor such as CD28, 4-1 BB, DAP10, 0X40, or ICOS.
  • Third generation of CARs include receptors encompassing 2 costimulatory domains combined with an activation domain in their cytoplasmic domain, for example CD20-specific CD28/4-1 BB/O ⁇ 3z.
  • the co-receptor may be cloned into a third- generation self-inactivating lentiviral vector such as pCCL under the control of an internal promoter (e.g. PGK or EFa) either alone or linked to chimeric antigen receptor targeting tumour antigens (e.g. CD19, CD20) via a self-cleaving peptide or IRES element.
  • T cells can be activated using anti- Cd3/CD28 reagents, transduced, expanded and tested in functional assays. These may include cytokine release assays, proliferation and cytotoxicity experiments.
  • the genetically engineered cell may be a T cell, suitably a CD8+ T cell, including a population of such cells.
  • the cell or population of cells may also be a CAR T cell in which the cell or cells have been modified to express a chimeric antigen T cell receptor.
  • the invention may related to a population of genetically engineered cells which all express an identical receptor (e.g. a TCR and/or a CAR) and also express a coreceptor (e.g. a FCRL3, FCRL6, and/or a LRRN3 co-receptor).
  • Such a population of cells may have a defined improved function (e.g. improved killing activity) compared with a control population lacking said co-receptor, as a population of cells with the same receptor but with a different co-receptor.
  • a nucleic acid sequence encoding a chimeric antigen receptor and a co-receptor selected from the group consisting of Fc-Receptor- Like-3 (FCRL3), Fc-Receptor-Like-6 (FCRL6), and Leucine-Rich-Repeat-Neuronal-3 (LRRN3).
  • FCRL3 Fc-Receptor- Like-3
  • FCRL6 Fc-Receptor-Like-6
  • LRRN3 Leucine-Rich-Repeat-Neuronal-3
  • the nucleic acid sequence may be natural, synthetic or recombinant. It may, for example, be cDNA, PCR product or a genomic sequence. It may be isolated, or as part of a plasmid, vector or host cell.
  • a plasmid is a circular extrachromosomal DNA molecule with the ability to replicate independently of chromosomal DNA.
  • a plasmid may be used to introduce an expression cassette into a host cell. Plasmids may also be used to express a polypeptide in a host cell. For example, a bacterial host cell may be transfected with a plasmid capable of encoding a particular polypeptide, in order to express that polypeptide.
  • the term also includes yeast artificial chromosomes and bacterial artificial chromosomes which are capable of accommodating longer portions of DNA.
  • a promoter is a region of DNA with a specific sequence that initiates the transcription of a particular gene or genes. Promoters used for the expression of heterologous genes include constitutive and inducible promoters. Examples of such promoters, include but are not limited to PGK or EFa.
  • the promoter comprises a nucleotide sequence that is substantially homologous to the sequence set forth in Fig 6, 10, or 1 1 .
  • Nucleic acid sequences with greater than 20% identity are considered to be homologous sequences.
  • substantially homologous refers to sequences exhibiting at least 60% or 70%, preferably means at least 80%, more preferably at least 90%, and most preferably at least 95%, 96%, 97%, 98%, 99% or greater identity.
  • the sequence has at least 80% or more (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc.) homology with the sequence set forth in Fig 6, 10 or 1 1 .
  • Sequence comparisons to determine homology can be carried out using readily available sequence comparison software. Examples include but are not limited to BLAST (see Ausubel et al., 1999 Short Protocols in Molecular Biology, 4th Ed - Chapter 18) and FASTA (Altschul et al., 1990 J. Mol. Biol. 403-410). Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60).
  • a vector comprising a nucleic acid sequence according to the second aspect of the invention.
  • the vector may be a lentiviral virus, for example pCCL.
  • the vector may comprise the nucleic acid sequence either alone or linked to chimeric antigen receptor targeting tumour antigens (e.g. CD19, CD20 etc.), via a self-cleaving peptide or IRES element.
  • lentiviral vector is LeGO-iG2 (addgene) (Weber et al. (2008) Mol. Ther. 16(4), 698-706), or pCCL-c-MNDU3-X (Logan et al (2004) Hum Gene Ther 15(10), 976-988).
  • the vector may comprise CMV promoter and optionally also an internal SFFV promoter.
  • Other internal promoters include PGK or EFa. Additional self-cleaving peptides or IRES elements may be present also.
  • Figure 8 An example of one embodiment of this aspect of the invention is shown in Figure 8 where the nucleic acid sequence encoding a co-receptor is the sequence coding for FCRL3.
  • An alternative vector may be a self-inactivating lentiviral vector such as pCCL suitably under the control of an internal promoter (e.g. PGK or EFa) either alone or additionally comprising a self-cleaving peptide or IRES element.
  • an internal promoter e.g. PGK or EFa
  • Vectors of the invention are described in Figures 8, 9, 12 and 13.
  • nucleic acid sequences and/or vectors include isolated forms of the nucleic acid and/or vector, suitably in the form of cDNA.
  • a cell comprising a vector according to the fourth aspect of the invention.
  • the cell may be a T cell, suitably a CD8+ T cell, including a population of such cells.
  • a cell according to the first aspect a nucleic acid sequence according to the second aspect, a vector according to the third aspect or a cell according to the fourth aspect for use in medicine.
  • Embodiments of the invention in accordance with this aspect of the invention therefore include a method of treatment of a disease comprising administration of an effective amount of the cell, nucleic acid sequence, vector or cell comprising a vector to a subject in need thereof.
  • the subject may be a human or a non-human animal, for example a non-human mammal.
  • Such uses in medicine may find greatest application in the treatment of cancer, a viral infection, an auto-immune disease or inflammation.
  • the treatment of cancer may comprise enhanced activity in T cell mediated killing of tumour cells.
  • This aspect of the invention therefore also extends to and includes use of a cell, nucleic acid sequence, vector or cell comprising a vector according to the invention in the manufacture of a medicament for the treatment of cancer, a viral infection, an autoimmune disease or inflammation.
  • Cell-based treatments of cancer using genetically engineered cells of the invention may be of particular use.
  • nucleic acids and/or vectors of the invention may be used effectively also, such as to increase FCRL3/FCRL6/LRRN3 co-receptor expression for the purpose of increasing T cell killing activity in genetically engineered cells of the invention.
  • the cancer may be a solid tumour, for example a sarcoma, a carcinoma or a lymphoma.
  • the cancer may be a haematological cancer such as a leukaemia.
  • the viral infection may be the result of infection of a subject by a retrovirus (for example, a human T-lymphotropic virus (for example HTLV-1 , -2, -3, or -4), a human immune deficiency virus (for example HIV-1 or HIV-2).
  • a retrovirus for example, a human T-lymphotropic virus (for example HTLV-1 , -2, -3, or -4), a human immune deficiency virus (for example HIV-1 or HIV-2).
  • the inflammation may be rheumatoid arthritis, ankylosing Spondylitis (AS), antiphospholipid antibody syndrome (APS), gout, inflammatory arthritis, myositis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus (SLE or lupus), or vasculitis.
  • the auto-immune disease may be inflammatory bowel disease (IBD), multiple sclerosis, Guillain-Barre syndrome, diabetes mellitus (type 1 diabetes), psoriasis, chronic inflammatory demyelinating polyneuropathy.
  • Cells for use according to the invention may be obtained from any suitable source.
  • the cells may be autologous, i.e. isolated from the same patient to whom the genetically engineered cells are subsequently administered after modification of the cells.
  • Such autologous cells may be derived from the patient according to any generally suitable procedure.
  • a suitable procedure for obtaining lymphocytes, e.g. T cells from the blood of a patient is apheresis (more specifically by means of leukapheresis).
  • the patient is a human subject.
  • the cells may be obtained from the blood of a patient, subsequently genetically modified (e.g. by transduction or transfection) to express a nucleic acid sequence as defined herein which encodes a co-receptor (e.g. a FCRL3, FCRL6, and/or a LRRN3 co-receptor), optionally cultured and expanded ex vivo, and then returned to the circulating blood of the patient by infusion.
  • a co-receptor e.g. a FCRL3, FCRL6, and/or a LRRN3 co-receptor
  • the cells may also additionally be genetically engineered to express a modified T cell receptor, or a heterologous T cell receptor, or a CAR, or a mixture thereof.
  • cells obtained and prepared in this way can be stored (e.g. by cryopreservation) prior to use in suitable containers or packs, such as ready-to-use packs for infusion of the modified cells back into the patient.
  • the present invention therefore provides CAR-T cells which recognise cancer cells using a chimeric antigen receptor that combines an antibody recognition domain and the downstream signaling machinery of a TCR which have also been transduced or transfected to coexpress Fc-Receptor-Like-3 (FCRL3) to enhance killing of cancer cells.
  • a chimeric antigen receptor that combines an antibody recognition domain and the downstream signaling machinery of a TCR which have also been transduced or transfected to coexpress Fc-Receptor-Like-3 (FCRL3) to enhance killing of cancer cells.
  • FCRL3 modified HTLV-1 specific CD8 T-cells which have been transduced or transfected to co-express Fc-Receptor-Like-3
  • TILS Tumour invasive lymphocytes
  • FCRL3 Fc-Receptor-Like-3
  • the method of treatment may further comprise the administration of another therapeutic agent.
  • the therapeutic agent may be administered separately, simultaneously or sequentially with the cells, nucleic acid, vector or cell comprising a vector of the invention.
  • the subject may also receive radiation therapy and/or chemotherapy prior to, during or after the administration of the cells, nucleic acid, vector or cell comprising a vector of the invention.
  • kits comprising cell, nucleic acid, vector or cell comprising a vector as defined above and a physiologically acceptable diluent or adjuvant.
  • a specific binding molecule which binds to a receptor selected from the group consisting of Fc-Receptor-Like-3 (FCRL3), Fc-Receptor- Like-6 (FCRL6), and Leucine-Rich-Repeat-Neuronal-3 (LRRN3) for use in medicine.
  • FCRL3 Fc-Receptor-Like-3
  • FCRL6 Fc-Receptor- Like-6
  • LRRN3 Leucine-Rich-Repeat-Neuronal-3
  • Embodiments of the invention in accordance with this aspect of the invention therefore include a method of treatment of a disease comprising administration of an effective amount of the specific binding to a subject in need thereof.
  • the subject may be a human or a non-human animal, for example a nonhuman mammal.
  • Such uses in medicine may find greatest application in the treatment of cancer, a viral infection, an autoimmune disease or inflammation.
  • This aspect of the invention therefore also extends to and includes use of a specific binding molecule of the invention in the manufacture of a medicament for the treatment of cancer, a viral infection, an autoimmune disease, or inflammation. Examples of such diseases are as described above.
  • FCRL3 may be in the treatment of rheumatoid arthritis or T-cell lymphoma, including cutaneous T cell lymphoma. It is envisaged that some particular uses concerning specific binding molecules to FCRL6 and LRRN3 may be in the treatment of an autoimmune disease such as rheumatoid arthritis or multiple sclerosis. Similarly, other compounds which inhibit the function of these receptors, including approaches using CRISPR, could be used to equal effect to inhibit and down-regulate the receptors.
  • the specific binding molecule may be an antibody or a fragment thereof, or an aptamer. Antibodies to FCRL3 are available from BD Pharmingen (catalogue reference 565056) and R&D Systems (catalogue reference FAB3126P).
  • an antibody molecule is made up of two identical heavy (H) and two identical light (L) chains held together by disulphide bonds. Each heavy chain comprises an Fc polypeptide. The two Fc polypeptides from the two heavy chains dimerise to form the Fc region of the antibody molecule.
  • Fc region refers to the constant region of an antibody excluding the first constant region immunoglobulin domain of the heavy chain (CH1) that interacts with the constant portion of the light chain (CL) forming a CH1 -CL domain pair.
  • an Fc region comprises the last two constant region immunoglobulin domains (CH2 and CH3) of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM (CH2, CH3 and CH4).
  • the terms“antibody” and“antibodies” include references to engineered antibodies which include other binding domains, such as bispecific antibodies.
  • the antibodies may be monoclonal or polyclonal.
  • Polyclonal antibodies can be raised by stimulating their production in a suitable animal host (e.g. a mouse, rat, guinea pig, rabbit, sheep, goat or monkey) when the substance of the present invention is injected into the animal. If necessary an adjuvant may be administered together with the substance of the present invention.
  • the antibodies can then be purified by virtue of their binding to a substance of the present invention.
  • Monoclonal antibodies can be produced from hybridomas. These can be formed by fusing myeloma cells and spleen cells which produce the desired antibody in order to form an immortal cell line. This is the well-known Kohler & Milstein technique ( Nature 256 52-55 (1975)).
  • the present invention includes derivatives thereof which are capable of binding to substances of the present invention.
  • the present invention includes antibody fragments and synthetic constructs. Examples of antibody fragments and synthetic constructs are given by Dougall et al in Tibtech 12 372-379 (September 1994).
  • Antibody fragments include any portion of a full-length antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, scFv, Fv, dsFv diabody and Fd fragments.
  • single chain variable fragment refers to an Fv fragment in which the heavy chain domain and the light chain domain are linked.
  • One or more scFv fragments may be linked to other antibody fragments (such as the constant domain of a heavy chain or a light chain) to form antibody constructs having one or more antigen recognition sites.
  • Other synthetic constructs include CDR peptides. These are synthetic peptides comprising antigen binding determinants. Peptide mimetics may also be used. These molecules are usually conformationally restricted organic rings which mimic the structure of a CDR loop and which include antigen-interactive side chains.
  • Synthetic constructs include chimeric molecules.
  • humanised (or primatised) antibodies or derivatives thereof are within the scope of the present invention.
  • An example of a humanised antibody is an antibody having human framework regions, but rodent hypervariable regions.
  • Synthetic constructs also include molecules comprising a covalently linked moiety which provides the molecule with some desirable property in addition to antigen binding.
  • the moiety may be a label (e.g. a fluorescent or radioactive label) or a pharmaceutically active agent.
  • kits comprising a specific binding molecule which binds to a receptor selected from the group consisting of Fc-Receptor-Like-3 (FCRL3), Fc-Receptor-Like-6 (FCRL6), and Leucine-Rich-Repeat-Neuronal-3 (LRRN3) and a physiologically acceptable diluent or adjuvant.
  • FCRL3 Fc-Receptor-Like-3
  • FCRL6 Fc-Receptor-Like-6
  • LRRN3 Leucine-Rich-Repeat-Neuronal-3
  • FCRL3 is a novel cytotoxic (CD8) T-cell co-receptor that enhances TCR downstream signalling to increase the probability of generating sufficient signal to trigger lytic granule upon encounter with a target cell thus enhancing killing.
  • Overexpression of this molecule in T-cell therapy products may enhance target cell killing i.e. increase killing of cancer or viral infected target cells by CD8+ T-cells.
  • a unique population of ex vivo CD8+ T-cells is marked by expression of this receptor.
  • the present invention therefore provides a CD8+ T-cell population characterised by expression of FCRL3 with enhanced efficacy for T-cell therapy products.
  • the other co-receptors disclosed herein, FCRL6 and/or LRRN3, are similarly able to enhance T cell killing activity.
  • a cell comprising a receptor that comprises an antigen binding domain and a T-cell activating function and at least one coreceptor which modulates the activity of the receptor in which the co-receptor is selected from the group consisting of Fc-Receptor-Like-3 (FCRL3), Fc-Receptor-Like-6 (FCRL6), and Leucine-Rich- Repeat-Neuronal-3 (LRRN3).
  • FCRL3 Fc-Receptor-Like-3
  • FCRL6 Fc-Receptor-Like-6
  • LRRN3 Leucine-Rich- Repeat-Neuronal-3
  • Figure 1 shows functionality of TCR-identical HLA-B*0801 -FL8-specific CTL clones.
  • A Representative flow cytometry plots showing p24 antigen expression in C8166 cells after incubation with clonal CTLs from LTNP005 (A3, A9, A17, or A20) at the indicated E:T ratios. Uninfected target cells were used as the negative control. Infected target cells cultured alone were used as the positive control. The HLA-A*0201 -SL9-specific clone G10 was included as a TCR-specificity control. Data represent two independent experiments.
  • Figure 2 shows characterization of effector functions in TCR-identical HLA-B*0801 -FL8- specific CTL clones from LTNP005.
  • A Pie charts indicate the percentage of clonal A3 or A20 CTLs responding to a range of cognate peptide concentrations. Three effector functions were measured simultaneously: 1 function, CCL4; 2 functions, CCL4 + CD107a; 3 functions, CCL4 + CD107a + IFNy.
  • S Secretion of IFNy and TNF by clonal A3 or A20 CTLs after incubation for 24 hr with HLA-matched CD4 + T cells infected for 72 hr with the indicated TCID50 doses of HIV-1 . Bar height indicates the mean of triplicates.
  • C Secretion of CCL4, IFN-g, TNF, and IL-2 by clonal A3 or A20 CTLs after incubation for 24 hr with phytohaemagglutinin (PHA) or phorbol myristate acetate and ionomycin (PMA and IONO). Bar height indicates the mean of triplicates.
  • D Hierarchical clustering and heatmap of differentially expressed genes in clonal A3 or A20 CTLs after stimulation for 6 hr with cognate peptide (2 mM). The top 32 genes in either direction are shown. Each column represents a sample, and each row represents a gene. The intensity of red/blue colour indicates the relative quantity of mRNA bound to each probe (key).
  • TNFSF10 tumour necrosis factor
  • LTA lymphotoxin alpha
  • GNLY granulysin
  • FASL Fas ligand
  • PRF perforin
  • GZMB granzyme B
  • TRAIL TRAIL
  • DNA isolated from clonal A3 or A20 CTLs was bisulfite converted, amplified by PCR, and sequenced to assess the frequency of methylated cytidine residues situated within CpG dinucleotides in the core TNF promoter from amino acid residues -200 to -1 17 (red boxes).
  • a representative sequencing screen for residues -171 to -1 19 is illustrated for each population (A3, left; A20, right). Each line represents one sequence, methylated cytidines are denoted by black circles, and unmethylated cytidines are denoted as green circles.
  • Figure 3 shows transcriptome analysis of resting TCR-identical HLA-B*0801 -FL8-specific CTL clones.
  • A Tetramer avidity assay. Clonal A3, A17, or A20 CTLs were stained with the indicated concentrations of the HLA-B*0801 -FL8 tetramer. Data represent three independent experiments.
  • B Hierarchical clustering and heatmap of 140 genes with altered expression in clonal A20 vs. A3 CTLs (absolute fold change of at least ⁇ 2 >; P ⁇ 0.01 by ANOVA). Each column represents a sample and each row represents a probe from the bead array that maps to a gene in the Ensembl database.
  • the colour represents the relative quantity of complementary RNA directly hybridized to each probe for each sample, scaled for each row to range from -1 (blue) to +1 (red) as indicated (key). Some genes are represented by more than one probe. Data represent three independent experiments with three generations of each clone.
  • C Bar chart illustrating the mean absolute fold change (x- axis) in gene expression of selected cell surface receptors in resting clonal A20 vs. A3 CTLs (P ⁇ 0.01 by ANOVA). Protein name, signalling motif, and comments are shown in Table 2.
  • D Real-time PCR analysis of mRNA extracted from resting clonal A20 vs. A3 CTLs sorted to > 99% purity by flow cytometry.
  • Error bars indicate mean ⁇ SD. Data represent three independent experiments with three generations of each clone.
  • E and F Real-time PCR analysis of mRNA extracted from resting clonal E833-30 vs. E833-13 CTLs (E) or resting clonal G713-20 vs. G713-4 CTLs (F).
  • E clone E833-30 is the most antigen-sensitive (Fig. 1 E).
  • clone G713-20 is the most antigen-sensitive (Fig. 1 E). Error bars indicate mean ⁇ SD. Data represent two independent experiments with two generations of each clone.
  • FIG. 4 shows FCRL3 association with TCR signal transduction and degranulation kinetics.
  • B Phosphorylated forms of p44/42 MAPK in clonal A20 vs.
  • A3 CTLs were quantified by phospho-flow cytometry after stimulation for 10 min with cognate peptide (10 mM). ****p ⁇ 0.0001 (Student t-test). Data represent two independent experiments with two generations of each clone.
  • SFFV spleen focus-forming virus
  • E A representative flow cytometry histogram showing phosphorylated p44/42 MAPK in Jurkat cell lines expressing FCLR3 or the corresponding Empty Vector after stimulation for 10 min with OKT3.
  • Figure 5 shows ex vivo ITAM/ITIM expression in single TCR Vp 13.2 + HLA-B*0801 -FL8 tetramer-binding CD8 + T cells sorted directly ex vivo from donor LTNP005.
  • A Hierarchical clustering and heatmap of ITAM/ITIM genes and housekeeping genes ACTB, GAPDH, and CD8A. Each column represents a gene, and each row represents a cell.
  • B Comparison of the proportions of CD8 + T cells expressing the ITAM/ITIM genes FCRL3, FCRL6, or LRRN3 in 2003 vs. 2004.
  • Figure 7 shows amino acid sequences for human FCRL3 isoforms in comparison to the canonical sequence (a) canonical sequence of 734 amino acids; (b) isoform 3; (c) isoform 6; and (d) isoform 7.
  • Figure 8 shows the nucleic acid sequence of the lentiviral vector comprising the human FCRL3 nucleic acid sequence with the vector residues shown in upper case and the FCRL3 encoding residues shown in lower case.
  • Figure 9 shows the plasmid map for the vector LeGo-iG2.
  • Figure 10 shows the nucleic acid sequence encoding human LRRN3 (a) with accession reference NM_001099660.1 , transcript variant 1 , and the corresponding amino acid sequence (b) with accession reference NP_001093130.1 , and (c) a nucleic acid sequence encoding LRRN3 which has been codon optimized for expression.
  • Figure 11 shows the nucleic acid sequence encoding human FCRL6 (a) with accession reference NM_001004310.2, transcript variant 1 , and the corresponding amino acid sequence (b) with accession reference NP_001004310.2, and (c) a nucleic acid sequence encoding LRRN3 which has been codon optimized for expression.
  • Figure 12 shows the nucleic acid sequence of the lentiviral vector comprising the human FCRL6 nucleic acid sequence with the vector residues shown in upper case and the FCRL6 encoding residues shown in lower case.
  • Figure 13 shows the nucleic acid sequence of the lentiviral vector comprising the human LRRN3 nucleic acid sequence with the vector residues shown in upper case and the LRRN3 encoding residues shown in lower case.
  • PBMCs Peripheral blood mononuclear cells
  • the FLKEKGGL peptide was synthesized by FMOC to at least 90% purity confirmed by HPLC. Tetrameric HLA-B*0801 -FL8 complexes were generated as described previously (12). Directly conjugated antibodies were obtained from the following vendors: (i) a-TCR Vp 13.2 (PE), a-CD94 (PE), and a-p24 antigen (clone KC57 RD1 ; PE) (Beckman Coulter); (ii) a-CD4 (APC), a-CD8 (FITC, Pacific Blue, PE, or PE-Cy7), a-CD27 (APC), a-CD28 (FITC), a-CCL4 (PE), a-CD107a (FITC or APC), ot-IFNy (PE-Cy7), a-TNFa (APC), a-PD-1 (APC), and a-granzyme B (PE) (BD Biosciences); (iii) a-perforin (clone B
  • PBMCs or clonal CTLs were incubated with titrated amounts of tetramer (PE) for 15 min at 37°C. Surface antibodies were then added for 20 min at 4°C. Cells were washed and, if intracellular staining was required, fixed/permeabilized using a BD Cytofix/Cytoperm Kit (BD Biosciences). Data were acquired using a FACS Cyan flow cytometer (Beckman Coulter) and analyzed with FlowJo software (Tree Star).
  • PE tetramer
  • Tetramer-binding cells were sorted from thawed PBMC samples collected from HIV-1 -infected individuals (Table 1) using anti-PE MicroBeads (Miltenyi Biotec) and plated at limiting dilution as described previously (Dong et al. (2004) J Exp Med 200(12): 1547-1557).
  • Table 1 shows TCR sequences and clonotyping for TCR identical HLA B*08-restricted FL8-specific CD8+ CTL Clones. Clonotype count and frequency are shown for the ex vivo HLA B*0801- restricted FL8-specific tetramer population from donor LTNP005 (in bold) and TCR -identical CTL- clone pairs (LTNP005 A3 and A20; E833 -13 and -30; G713-4 and -20).
  • Clones were expanded by periodic restimulation using mixed irradiated allogeneic PBMCs with phytohemagglutinin (PHA; 40 mg/mL) and recombinant human IL-2 (200 lll/mL).
  • PHA phytohemagglutinin
  • human IL-2 200 lll/mL
  • An HLA-A*0201 - restricted HIV p17 Gag-specific clone (G10) was generated as described previously (Lee etal. (2004) J Exp Med 200(1 1): 1455-1466).
  • the CD4 + T cell line C8166 was obtained from the National Institute of Health (NIH) AIDS Reference and Reagent Program and cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 mg/mL streptomycin sulphate, and 1 .7 mM sodium glutamate.
  • Cell lines and CTL clones were negative on regular screening for mycoplasma contamination. All clones were cultured under identical conditions and transcriptome analysis was performed on day 14 post-restimulation. Day 14 was validated by gene expression studies showing that contaminating feeder cells were present at ⁇ 0.1 % and CTL clones achieve a stable state at this time point.
  • FCRL3 (NCBI accession number NM_052939.3) was synthesized and cloned into the lentiviral vector Lego.iG2 (Addgene, Weber) by Blue Heron. Lentiviral particles were produced by transient transfection of HEK293T/17 cells using the calcium phosphate method. HEK293T/17 cells were transfected with lentiviral vector (Lego.iG2 or FCRL3.Lego.iG2) DNA together with the third- generation HIV-1 -based packaging plasmids PMD2.G, pMDLg/pRRE, and pRSV-Rev (Addgene, Trono).
  • Jurkat cells were transduced with 10-fold serial dilutions of frozen virus in 96-well plates.
  • Polybrene (8 mg/mL) was added to the wells, and the plate was centrifuged at 2,5000 rpm for 40 min at 25°C.
  • Cells were analyzed by flow cytometry for eGFP expression on day 5. Titers were calculated from the dilution that rendered 1-20% of the cells GFP + .
  • Jurkat cells were transduced with Lego.iG2 or FCRL3.Lego.iG2 viruses at a multiplicity of infection of 10. On day 5, GFP high cells were sorted by flow cytometry and seeded at 1 , 3, or 5 cells per well in a 96-well plate. FCRL3 expression was confirmed by flow cytometry.
  • the Lego.iG2 cell line was isolated from a well containing 3 cells, and the FCRL3.Lego.iG2 cell line was isolated from a well containing 5 cells.
  • Antigen sensitivity was determined using standard chromium release assays.
  • 51 Cr-labelled C8166 cells were plated at 5 x 10 4 cells/well with or without clonal CTLs at an effectontarget (E:T) ratio of 3:1 in the presence of peptide at a final concentration of 0-10 mg/mL.
  • E:T effectontarget
  • Released 51 Cr in the harvested supernatant was measured using a b-plate counter (WALLAC).
  • C8166 cells were infected with 1 x TCIDso HIV-1 MN (NIBSC AIDS Reagents) for 90 min at 37°C, washed three times, and re-suspended in H10 medium (RPM1 1640 medium supplemented with 10% heat-inactivated human serum) containing IL-2 (200 U/mL).
  • Infected target cells were plated at 5 x 10 4 cells/100 mI with 2.5 x 10 3 clonal CTLs or appropriate dilutions thereof in triplicate in a 96-well plate and incubated for 96 hr at 37°C.
  • Positive control (infected C8166 cells alone) and negative control (uninfected C8166 cells) wells were included, together with an HLA-mismatched control (the HLA-A*0201 -SL9-specific CTL clone G10). Additional wells were set up to allow for spectral overlap.
  • a p24 ELISA Kit (ImmunoDiagnostics Inc.) was used to detect p24 antigen in 50 mI of neat supernatant as instructed.
  • CTL-mediated suppression was expressed as the percentage reduction in average p24 protein at day 4 relative to the average p24 content of infected C8166 cells alone (positive control). Cellular expression of p24 in C8166 cells was determined concomitantly by flow cytometry.
  • Clonal CTLs were stimulated for 24 hr alone in the presence of PHA (40 mg/mL) or phorbol myristate acetate (PMA; 50 ng/mL) and ionomycin (1 mg/mL), or at 10: 1 ratio with C8166 cells infected for 72 hr with three titrations of HIV-1 MN .
  • PHA 40 mg/mL
  • PMA phorbol myristate acetate
  • ionomycin 1 mg/mL
  • Cytokines in the culture supernatant were measured using a Human Cytokine 17-Plex Panel Assay (IL-1 b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL 17, G-CSF, GM-CSF, IFN-g, MCP-1 , CCL4, and TNF) in a suspension array system (Luminex 200; Bio-Rad Laboratories).
  • RNA from three generations of two clones was isolated from 3 x 10 6 cells after stimulation for 24 hr at 10:1 ratio with C8166 cells. Clonal CTLs were negatively selected using anti-CD4 MicroBeads (Miltenyi Biotec). Viable cells were counted using Trypan Blue, and total RNA was extracted using either a mirVana miRNA Isolation Kit (Applied Biosystems) or an RNeasy Kit (Qiagen). RNA integrity was measured using a Bioanalyzer (Agilent).
  • Genome-wide gene expression analysis was performed using a HumanHT-12 v4 Expression BeadChip containing 47,231 annotated probes (llumina). Total RNA was amplified and labelled during in vitro transcription with biotin, hybridized to the array, washed, stained with Cy3-Streptavidin, and scanned for quality control and gene detection using Genome Studio (lllumina). Data files are available at the Gene Expression Omnibus data repository under accession code XXX. Quantitative real-time PCR was performed using a 7500 System (Applied Biosystems). Primers specific for listed genes were obtained from Applied Biosystems.
  • Genomic DNA was extracted from each population using a PureGene DNA Purification Kit (Gentra Systems), and 500 ng of genomic DNA was converted using a Methylcode Bisulfite Conversion Kit (Invitrogen). Fragments generated by PCR were amplified separately using the following primers: - 237 amplification: 5’-TTT GTA TTT TGT TTG GAA GTT AGA AGG AAA TAG ATT A-3’ and 5’-AAA ACT TCC TTA ATA AAA CCC ATA AAC TCA TC-3’; -1030 amplification: 5’-AGA GTT GTG GGG AGA ATA AAA GGA TAA GG-3’ and 5’-AAA CAT TCT CCT ACC CAT TAC TAT AAT CAC ATC TC -3’. Products were subcloned into pCR4 TOPO TA (Invitrogen) and sequenced.
  • Jurkat Lego.iG2 and FCRL3.Lego.iG2 cells (1 x 10 6 /well) were incubated with soluble a-CD28 (BioLegend) and stimulated with plate-bound (1 mg/ml) a-CD3 (clone OKT3; BioLegend) for 10 min at 37°C.
  • Clonal CTLs (1 x 10 6 ) were stimulated with peptide-pulsed C8166 cells at an E:T ratio of 10:1 for 10 min at 37°C. Stimulations were performed using the cognate FL8 peptide or a control peptide from the CMV pp65 protein (NLVPMVATV; residues 495-503).
  • nb 13.2 + CD8 + T cells were sorted using a FACS Aria flow cytometer (BD Biosciences) into 96-well plates containing CellsDirect One-Shot qRT-PCR Bufferwith Platinum Taq Polymerase and Superscript III Reverse Transcriptase (Invitrogen), 0.2x TaqMan gene-specific expression assays (Applied Biosystems), and Superaseln RNase inhibitor (Ambion). Immediately after cell sorting, samples were incubated for 10 min at 55°C, denatured for 2 min at 95°C, and amplified over 21 cycles of PCR (15 sec at 95°C; 4 min at 60°C). Negative control wells were run in parallel without Superscript III.
  • cDNA from each bulk sample was amplified from 100 cells over 18 cycles of RT-PCR.
  • Pre-amplified cDNA was diluted 1 :5 in TE buffer and then mixed with TaqMan Universal PCR Master Mix (Applied Biosystems).
  • the sample mix and TaqMan assays were loaded separately into wells of a 192.24 Gene Expression Dynamic Array (Fluidigm).
  • Example 1 Generation of TCR-identical CTL clones by expansion of single cells ex vivo
  • TCR is the key structure that mediates recognition of peptide-MHC class I complexes, yet it is not clear if TCR affinity, TCR avidity or events downstream of the TCR determine the variable antiviral efficacy among epitope-specific CTLS.
  • TCR-identical CTL clones were generated from three HIV-1 -infected individuals with immunodominant HLA-B*0801 -restricted CD8 + T cell responses specific for FL8.
  • tetramer defined populations were characterized by a dominant TCR clonotype in two individuals, LTNP005 and E833, and a codominant TCR clonotype in a third individual, G713, all of which used TRBV6-2 in conjunction with distinct TRBJ, TRAV, and TRAJ genes (12).
  • donor LTNP005
  • TRBV 6-2 + also known as Vp 13.2
  • tetramer-binding population was dominated by the use of a single TCR (Table 1).
  • LTNP005 had maintained a normal CD4 + T cell count for 14 years without anti-retroviral therapy (ART).
  • ART anti-retroviral therapy
  • TCR-identical CTL clones were found to have distinct antiviral efficacy. All four clones isolated from LTNP005 expressed an identical TCR (Table 1). Each clone (A3, A9, A17, and A20) had a distinct ability to suppress HIV-1 replication in an HLA-matched CD4 + T cell line (C8166) infected with HIV- 1 MN . In vitro viral suppression required MHC class I restriction and appeared to depend on contact- dependent killing, as suppression correlated with elimination of p24 + cells by flow cytometry (Fig. 1 A). Heterogeneity in killing capacity was more striking at lower effector: target (E:T) ratios, with suppressive activity ranging from 10-90% at an E:T ratio of 1 :16 (Fig.
  • the peptide concentration required to trigger half-maximal killing (ECso) was determined in shortterm chromium release assays.
  • CTL polyfunctionality has been associated with antigen sensitivity. Accordingly, CD107a mobilization and the production of IL-2, TNF, IFNy, and CCL4 was assessed in peptide titration experiments. For this purpose, the experiment focused on two clones from LTNP005. Clone A20 was highly antigen sensitive and displayed potent antiviral efficacy, whereas clone A3 was moderately antigen sensitive and displayed moderate antiviral efficacy. At limiting peptide concentrations, clone A20 was more polyfunctional than clone A3 (Fig. 2 A), but unexpectedly failed to secrete TNF.
  • TNF production was not observed in clone A20 in response to HIV-1 MN -infected HLA-matched CD4 + T cells (Fig. 28) and could not be induced by stimulation with either phytohaemagglutinin (PHA) or phorbol myristate acetate (PMA) (Fig. 2 C).
  • PHA phytohaemagglutinin
  • PMA phorbol myristate acetate
  • TNF normalized fluorescence intensity
  • Lytic granule release was measured as a correlate of CD107a mobilization on the cell surface.
  • a higher proportion of clonal A20 CTLs were CD107a + compared with clonal A3 CTLs 6 hours after stimulation with peptide-pulsed C8166 cells (27% vs. 1 1 %) (Fig. 2 A). Cytotoxic effector molecules were therefore examined for comparative transcript abundance (Fig. 2 E). There was no difference in the abundance of mRNA transcripts for Fas ligand (FASL), TRAIL (TNFSF10), granzyme B (GZMB), and perforin (PRF).
  • FASL Fas ligand
  • TNFSF10 TRAIL
  • GZMB granzyme B
  • PRF perforin
  • FCERIG Fc-receptor-like molecules
  • FCRL3 Fc-receptor-like molecules
  • FCRL6 which originate from one gene complex
  • an immunoglobulin superfamily on chromosome 1 q that also encodes the TCR complex signalling protein O ⁇ 3z and the BCR coreceptor FCRL1 .
  • These proteins incorporate cytoplasmic domain ITAMs and/or ITIMs.
  • Clone A20 showed higher expression of three genes, encoding three ITAMs and one ITIM ( FCERIG , FCRL3, and TYROBP), whereas clone A3 showed higher expression of FCRL6, which encodes one ITIM, as well as KIR2DL3 and KIR2DL4, both of which have an ITIM in their long cytoplasmic tails (Fig. 3C).
  • Table 2 shows cell Surface Receptors differentially expressed in Clone A20 compared to Clone A3. The protein names, signalling motifs and comments related to the function of ten genes encoding the selected cell surface receptors in Fig
  • Clone A3 also expressed significantly higher levels of LRRN3, a gene first isolated from neuronal tissue that encodes a potential cytoplasmic domain ITIM. As expected from the antibody staining data, there was no differential expression of genes encoding the two TCR chains or CD8a or OW8b. Real-time PCR analysis confirmed differential expression for 13 of 15 selected genes, including FCRL3, FCRL6, TYROBP, and LRRN3. To ensure that these genes were indeed differentially expressed and not artifacts of contamination by feeder cells or C8166 target cells, the two clones were sorted to > 99% purity by flow cytometry. Repeat real-time PCR analysis using these ultra-pure templates confirmed differential mRNA expression for FCRL3, FCRL6, FCERIG, and LRRN3 (Fig. 3D).
  • Example 6 FCRL3 enhances signalling triggered via the TCR
  • FCRL3 contains both an ITAM and an ITIM.
  • the effects of FCRL3 on TCR signal transduction were investigated using phospho-flow cytometry to assess the phosphorylation of p44/42 mitogen- activated protein kinase (MAPK) extracellular signal-related kinase 1/2 (ERK1/2).
  • MAPK mitogen- activated protein kinase
  • FCRL3 was engineered into a lentiviral vector (Fig. 4D) encoding an internal ribosome entry site (IRES)-driven green fluorescent protein (GFP) to enable fluorescence-activated cell sorting of transduced cells and the generation of two Jurkat cell lines, one that stably expressed the empty vector and one that stably expressed FCRL3.
  • IRS internal ribosome entry site
  • GFP green fluorescent protein
  • Example 7 Ex vivo expression of ITAM/ITIM receptors in TCR-identical CTLs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une cellule génétiquement modifiée comportant un récepteur comprenant un domaine de liaison à l'antigène et une fonction d'activation de lymphocyte T et au moins un co-récepteur modulant l'activité du récepteur, la cellule surexprimant le co-récepteur, et ledit co-récepteur étant choisi dans le groupe constitué par FCRL3, FCRL6, et LRRN3, et leurs utilisations en médecine, par exemple dans le traitement du cancer, d'une inflammation, d'une maladie auto-immune ou d'une infection virale. L'invention concerne également des constructions d'acides nucléiques comprenant un co-récepteur choisi dans le groupe constitué par FCRL3, FCRL6, et LRRN3 et un lymphocyte T exprimant un récepteur à l'antigène chimérique, et leurs utilisations en médecine.
PCT/GB2019/053514 2018-12-11 2019-12-11 Cellules modifiées utiles pour une méthode thérapeutique Ceased WO2020120965A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820157.4A GB201820157D0 (en) 2018-12-11 2018-12-11 Method of treatment
GB1820157.4 2018-12-11

Publications (1)

Publication Number Publication Date
WO2020120965A1 true WO2020120965A1 (fr) 2020-06-18

Family

ID=65030170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2019/053514 Ceased WO2020120965A1 (fr) 2018-12-11 2019-12-11 Cellules modifiées utiles pour une méthode thérapeutique

Country Status (2)

Country Link
GB (1) GB201820157D0 (fr)
WO (1) WO2020120965A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103905A2 (fr) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps qui se lient spécifiquement à irta et son procédé d'utilisation
US20150004176A1 (en) * 2011-07-01 2015-01-01 Beckman Coulter, Inc. Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders
WO2016097231A2 (fr) * 2014-12-17 2016-06-23 Cellectis Récepteur d'antigène chimérique inhibiteur (icar ou n-car) exprimant un domaine de transduction non lymphocytaire t
WO2016174407A1 (fr) * 2015-04-27 2016-11-03 Ucl Business Plc Structure d'acide nucléique pour exprimer plus d'un récepteur d'antigène chimère
WO2016193696A1 (fr) * 2015-06-01 2016-12-08 Ucl Business Plc Cellule
WO2019068007A1 (fr) * 2017-09-28 2019-04-04 Immpact-Bio Ltd. Plate-forme universelle pour préparer un récepteur d'antigène chimérique inhibiteur (icar)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103905A2 (fr) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps qui se lient spécifiquement à irta et son procédé d'utilisation
US20150004176A1 (en) * 2011-07-01 2015-01-01 Beckman Coulter, Inc. Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders
WO2016097231A2 (fr) * 2014-12-17 2016-06-23 Cellectis Récepteur d'antigène chimérique inhibiteur (icar ou n-car) exprimant un domaine de transduction non lymphocytaire t
WO2016174407A1 (fr) * 2015-04-27 2016-11-03 Ucl Business Plc Structure d'acide nucléique pour exprimer plus d'un récepteur d'antigène chimère
WO2016193696A1 (fr) * 2015-06-01 2016-12-08 Ucl Business Plc Cellule
WO2019068007A1 (fr) * 2017-09-28 2019-04-04 Immpact-Bio Ltd. Plate-forme universelle pour préparer un récepteur d'antigène chimérique inhibiteur (icar)

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"NCBI", Database accession no. NM_052939.3
ALMEIDA ET AL., BLOOD, vol. 113, no. 25, 2009, pages 6351 - 636
ALTSCHUL ET AL., J. MOL. BIOL., 1990, pages 403 - 410
ATSCHUL ET AL., J. MOLEC. BIOL., vol. 215, 1990, pages 403
AUSUBEL ET AL., SHORT PROTOCOLS IN MOLECULAR BIOLOGY, 1999, pages 7-58 - 7-60
BETTS ET AL., BLOOD, vol. 107, no. 12, 2006, pages 4781 - 4789
DEVEREUX ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387
DONG ET AL., J EXP MED, vol. 200, no. 11, 2004, pages 1455 - 1466
DOUGALL ET AL., TIBTECH, vol. 12, September 1994 (1994-09-01), pages 372 - 379
FLERIN ET AL., J VIROL, vol. 91, no. 6, 2017
HALLE ET AL., TRENDS IMMUNOL, 2017
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 52 - 55
KULEMZIN S V ET AL: "FCRL6 receptor: Expression and associated proteins", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 134, no. 2, 30 January 2011 (2011-01-30), pages 174 - 182, XP027566468, ISSN: 0165-2478, [retrieved on 20101220] *
LOGAN ET AL., HUM GENE THER, vol. 15, no. 10, 2004, pages 976 - 988
MCMICHAELJONES, SCIENCE, vol. 330, no. 6010, 2010, pages 1488 - 1490
RITTER ET AL., PROC NATL ACAD SCI U S A, vol. 114, no. 32, 2017, pages E6585 - E6594
ROITT ET AL.: "Immunology", 1989, CHURCHILL LIVINGSTONE
SAEZ-CIRION ET AL., PROC NATL ACAD SCI USA, vol. 104, no. 16, 2007, pages 6776 - 6781
VALITUTTI ET AL., J EXP MED, vol. 183, no. 4, 1996, pages 1917 - 1921
WEBER ET AL., MOL. THER., vol. 16, no. 4, 2008, pages 698 - 706

Also Published As

Publication number Publication date
GB201820157D0 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
AU2021203481B2 (en) Chimeric antigen receptors (CARs), compositions and methods of use thereof
US20240342213A1 (en) Methods and Compositions for Cells Expressing a Chimeric Intracellular Signaling Molecule
JP6940406B2 (ja) キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
US12486514B2 (en) Method to specifically stimulate survival and expansion of genetically-modified immune cells
CN107074929B (zh) 嵌合自身抗体受体t细胞的组合物和方法
ES2979088T3 (es) Proteínas de fusión inmunomoduladoras y usos de las mismas
EP3469362B1 (fr) Récepteurs de lymphocytes t gamma delta restreints à l'antigène leucocytaire humain et leurs méthodes d'utilisation
JP2023052446A (ja) 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
KR102098985B1 (ko) Cs1-특이적 키메라 항원 수용체 가공된 면역 작동체 세포
CN114585646A (zh) Mage-a4 t细胞受体及其使用方法
KR20180050413A (ko) Hiv 감염을 치료하기 위해 t 세포를 리디렉션시키는 방법
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
KR20190016507A (ko) TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체
KR20230010228A (ko) 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars)
US20240026293A1 (en) Methods and Compositions for Cells Expressing a Chimeric Intracellular Signaling Molecule
CN116209455A (zh) 用于在细胞中表达多肽的核酸构建体
TWI886132B (zh) TGF-β受體及使用方法
TW202300528A (zh) 嵌合抗原受體
JP2024514355A (ja) キメラ抗原受容体（ｃａｒ）－ｔ細胞
US20230174622A1 (en) Epidermal growth factor receptor
WO2020120965A1 (fr) Cellules modifiées utiles pour une méthode thérapeutique
KR20250112252A (ko) 항-cd19 car-t 세포 치료법을 사용하는 루푸스 신염의 치료 방법
EP3790896A1 (fr) Polypeptides chimériques, molécules d'acide nucléique, cellules et procédés associés
US12496338B2 (en) CAR for treatment of HIV infection
WO2025125363A1 (fr) Cellules hôtes modifiées pour contourner la voie de co-stimulation cd28 et leurs utilisations pour induire des réponses immunitaires durables dans des conditions non inflammatoires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19824376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19824376

Country of ref document: EP

Kind code of ref document: A1